The final analysis of the phase 2 HERIZON-BTC-01 trial show a clinically meaningful benefit for zanidatamab in patients with treatment refractory HER2-positive biliary tract cancer
fondazionebonadonna.org/en/zanidatam...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Preoperative PAXG significantly improved event-free survival compared to mFOLFRINOX in patients with resectable pancreatic ductal adenocarcinoma
fondazionebonadonna.org/en/a-compari...
#FondazioneBonadonna #Oncology #CancerResearch
In HER2+ breast cancer patients a neoadjuvant therapy with a selected taxane plus trastuzumab but without carboplatin leads to similar benefits in pathological complete response and improves tolerability
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #CancerResearch #Oncology
The PATINA study coordinated in Italy by Fondazione Michelangelo, shows that adding palbociclib to standard therapy improves progression-free survival in hormone receptor-positive and HER2-positive metastatic breast cancer patients
fondazionemichelangelo.org/news-update/...
#BreastCancer #Oncology
Results from the phase 2 PRADO trial show favorable 5-years outcomes in overall survival with adjuvant ipilimumab plus nivolumab in stage III macroscopic melanoma
fondazionebonadonna.org/en/neoadjuva...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Clinical benefits on disease-free survival and overall survival with the addition of carboplatin to adjuvant epirubicin/cyclophosphamide followed by taxanes in early-stage triple-negative breast cancer
fondazionemichelangelo.org/news-update/... #FondazioneMichelangelo #Oncology #CancerResearch
Adding the bispecific anti-HER2 antibody anbenitamab to chemotherapy improved progression-free survival and overall survival in previously treated HER2-positive gastric cancer
fondazionebonadonna.org/en/anbenitam...
#FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social
Neoadjuvant intralesional darumon, a combination of two fibronectin-targeting immunocytokines, improved recurrence-free survival in patients with locally advanced melanoma
fondazionebonadonna.org/en/targeted-...
#FondazioneBonadonna #CancerResearch #Oncology
@mauriziocallari.bsky.social
Addition of camrelizumab to neoadjuvant chemotherapy significantly improves pathological complete response rate in early or locally advanced triple-negative breast cancer
fondazionebonadonna.org/en/neoadjuva...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Camrelizumab plus chemotherapy, compared to chemoradiotherapy, is a safe an effective neoadjuvant strategy in resectable esophageal squamous cell carcinoma
fondazionebonadonna.org/en/camrelizu...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Addition of carboplatin to sequential taxane-anthracycline neoadjuvant therapy increased overall survival in premenopausal women with triple-negative breast cancer
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #Oncology #CancerResearch @mauriziocallari.bsky.social
A combination of nivolumab and ipilimumab is associated with a high rate of durable responses in mismatch repair–deficient/microsatellite instability–high non colorectal cancers
fondazionebonadonna.org/en/a-combina...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
A promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in non-small-cell lung cancer patients with active brain metastases
fondazionebonadonna.org/en/efficacy-...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
On the occasion of World Cancer Day 2026, #FGB, with the support of the Prada Group and in collaboration with #ESO, announces the 3 winners of the fifth edition of the Fellowship named after Gianni Bonadonna. Press Release fondazionebonadonna.org/wp-content/u...)
#FondazioneBonadonna #PradaGroup
A new phase 3 trial shows the non-inferiority of three versus six months of adjuvant chemotherapy with oxaliplatin and a fluoropyrimidine in colorectal cancer fondazionebonadonna.org/en/three-ver...
#FondazioneBonadonna #Oncology #CancerResearch
In a phase 1 trial, universal base-edited CAR7 T cells induced remission in relapsed or refractory acute lymphoblastic leukemia allowing a successful stem-cell translplantation in most patients
fondazionebonadonna.org/en/universal...
#FondazioneBonadonna #CancerResearch @mauriziocallari.bsky.social
Sacituzumab govitecan as first-line therapy showed a significantly longer progression-free survival than chemotherapy in patients with advanced triple-negative breast cancer
fondazionebonadonna.org/en/sacituzum...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer
fondazionebonadonna.org/en/disease-f...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
In patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab improved disease-free survival and overall survival
fondazionebonadonna.org/en/a-ctdna-g...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Results from lidERA trial show a significant improvement in disease-free survival with the novel SERD giredestrant in HR+/HER2- early stage breast cancer
fondazionebonadonna.org/en/capivaser...
#FondazioneGianniBonadonna #CancerResearch #Oncology
@mauriziocallari.bsky.social
In a phase 3 trial the addition of neoadjuvant and adjuvant pembrolizumab to standard care improved clinical outcome in patients with advanced head and neck cancer
fondazionebonadonna.org/en/neoadjuva...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Adjiuvant abemaciclib added to endocrine therapy improves overall survival in patients with HR+/HER2- high risk early breast cancer
fondazionemichelangelo.org/news-update/...
#FondazioneMichelangelo #FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Results from TUXEDO-3 phase 2 trial show a promising clinical activity for the novel antibody-drug conjugate patritumab deruxtecan in breast cancer patients with acrive brain metastases
fondazionebonadonna.org/en/patrituma...
#FondazioneBonadonna #CancerResearch
@mauriziocallari.bsky.social
A new study identifies 7 tumor microenvironment types and shows how they can shape therapeutic response, recurrence and metastases development in breast cancer
fondazionebonadonna.org/en/the-relev...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social #Bianchini #Criscitiello
A lot of advances have emerged from the Joint International Conference 2025 Innovation in Oncology organized by FGB with Prada Group supporting partner, by Fondazione Michelangelo and by European School of Oncology
fondazionebonadonna.org/en/from-new-...
#FondazioneGianniBonadonna #CancerResearch
The Godard Cinema of Fondazione Prada hosted today the opening press conference of the “Joint International Conference 2025”. The event is organized by FGB with the support of #PradaGroup #FondazioneMichelangelo and @ESOncology .
fondazionebonadonna.org/wp-content/u...
#CancerResearch #Oncology
mRNA vaccines targeting non-tumor-related antigens are potent immune modulators capable of sensitizing tumors to immune checkpoint blockade
fondazionebonadonna.org/en/sars-cov-...
#FondazioneBonadonna #Oncology #CancerResearch @mauriziocallari.bsky.social
Capivasertib added to abiraterone with androgen deprivation therapy increases progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer
fondazionebonadonna.org/en/capivaser...
#FondazioneBonadonna #Oncology #CancerResearch
@mauriziocallari.bsky.social
Final overall survival data from SOLTI-1303-PATRICIA trial highlight the relevance of gene expression profiling in HER2+ breast cancer, validating the potential of non-chemotherapy approaches in selected patients
fondazionemichelangelo.org/it/notizie-e...
#FondazioneMichelangelo #CancerResearch
Adding radiotherapy to immunotherapy can have systemic immunomodulatory and antitumor effects and may be a way to overcome immunotherapy resistance in non-small cell lung cancer
fondazionebonadonna.org/en/pembroliz...
#FondazioneBonadonna #Oncology
@mauriziocallari.bsky.social